The session will focus on targeting metabolic pathways to combat the most prevalent cardiovascular disease. Metabolic reprogramming of the whole body, and specifically of cardiovascular system, often are the initial events in these diseases. Therefore, novel strategies and compounds directed at intermediary metabolism are being developed and already show high promise in the treatment of cardiovascular disease. However, these strategies present numerous challenges concerning their actual mechanism and potential, requiring in-depth unraveling of their metabolic actions. The invited speakers will present the most prominent experimental evidences for the prevention and treatment of cardiovascular diseases.
Defective D-Lactate Metabolism Induce Methylglyoxal Accumulation and Cause Cardiomyopathy